Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer

This study tests adebrelimab (an immune checkpoint inhibitor) combined with chemotherapy and targeted radiation (SBRT) given before surgery in patients with limited-stage small cell lung cancer, to determine whether this approach can improve the ability to completely remove the tumor. **You may be eligible if...** - You are aged 18–75 with confirmed limited-stage small cell lung cancer (T1–T3, N0–N1) that is surgically removable - You have not received prior treatment for this cancer - Your heart and lung function are adequate to tolerate surgery - You have good blood counts and organ function **You may NOT be eligible if...** - Your cancer cannot be completely removed by surgery - You have received prior immunotherapy (such as PD-1/PD-L1 inhibitors) - You have an active autoimmune disease or immune deficiency - You have active hepatitis B, hepatitis C, or HIV - You have severe heart disease or recent major surgery - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.